KYLEENA
MARKETED BY: BayerINDICATION: The FDA has approved Kyleena, a progestin-containing intrauterine system, for the prevention of pregnancy for up to 5 years.DOSAGE FORM: 1 sterile intrauterine system consisting of a T-shaped polyethylene frame with a steroid reservoir containing 19.5 mg of levonorgestrelFOR MORE INFORMATION: bayer.usYOSPRALA
MARKETED BY: Aralez PharmaceuticalsINDICATION: The FDA has approved Yosprala, a once-daily, fixed-dose combination of aspirin and omeprazole for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin-associated gastric ulcers.DOSAGE FORM: Tablets: 81 mg of aspirin/40 mg of omeprazole or 325 mg of aspirin/40 mg of omeprazoleFOR MORE INFORMATION: yosprala.comSTELARA
MARKETED BY: JanssenINDICATION: The FDA has approved Stelara (ustekinumab) for the treatment of moderately to severely active Crohnâ€™s disease in adults who have failed or were intolerant to treatment with immunomodulators or corticosteroids, but never failed treatment with a tumor necrosis factor (TNF) blocker or who failed or were intolerant to treatment with 1 or more TNF blockers.DOSAGE FORM: Intravenous infusion: 260, 390, or 520 mg, followed by 90-mg subcutaneous maintenance injections every 8 weeksFOR MORE INFORMATION: stelarainfo.comINVOKAMET XR
MARKETED BY: JanssenINDICATION: The FDA has approved Invokamet XR, a once-daily, fixed-dose combination of canagliflozin and metformin hydrochloride extended-release (XR). Invokamet XR is indicated for first-line use as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes.DOSAGE FORM: Tablets: 50 or 150 mg of canagliflozin and 500 mg or 1000 mg of metformin XRFOR MORE INFORMATION: janssen.com
